The Dysmenorrhea Treatment Market is projected to grow at a significant pace reaching a CAGR of approximately 8.3%, over the forecast period of 2022–2030, despite a considerable fall in product sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.
In a recent research report by Market Research Community, the dysmenorrhea treatment market is expected to surpass USD XX billion by the year 2030, from USD XX billion in 2021.
Menstrual cramps are severe cramps that start in the lower abdomen and spread to the back, this, and legs. Several women begin experiencing severe pain during early puberty, about five years after the start of their menstrual cycle medically called dysmenorrhea. The treatment used in dysmenorrhea is known as dysmenorrhea treatment.
The global prevalence of disorders such as endometriosis, the primary cause of secondary dysmenorrhea, is increasing. Endometriosis affects an estimated 1 in 10 women throughout their fertile years, or around 176 million people globally, according to an article titled “Understanding Endometriosis—the Basics” published in July 2021. This element is predicted to have a substantial influence on market growth. As a result of the aforementioned factors, the nonsteroidal anti-inflammatory medicine category is predicted to considerably contribute to market expansion.
North America is dominate the growth of the dysmenorrhea treatment market owing to the introduction of innovative products for treating the discomfort associated with primary and secondary dysmenorrhea. For example, in 2021, Pfizer Inc. and Myovant Sciences received FDA authorization for the assessment of a supplementary Novel Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) to treat mild to severe endometriosis pain. As a result of these reasons, the market for dysmenorrhea therapy in the United States is predicted to increase considerably over the forthcoming years.
The study is consolidated into major segments and further into sub-segments, such as by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), by Treatment Type (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Hormonal Therapy) to forecast the dysmenorrhea treatment market size by value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.
Lastly, the report includes a regional analysis and country analysis with the latest trends, along with the major key players including Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson & Johnson, and Alvogen..
Our Other Reports:
Market Research Community